Details of the Drug

General Information of Drug (ID: DMSVOZT)

Drug Name
Nifedipine
Synonyms
Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN]
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [1]
Premature labour JB00 Approved [2]
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
C08CA05: Nifedipine
C08CA: Dihydropyridine derivatives
C08C: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08: CALCIUM CHANNEL BLOCKERS
C: CARDIOVASCULAR SYSTEM
C08CA05: Nifedipine
C08CA: Dihydropyridine derivatives
C08C: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08: CALCIUM CHANNEL BLOCKERS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 346.3
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 25 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 10 mcg/L [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The total body clearance of drug is 450-700 mL/min [5]
Elimination
Nifedipine is 60-80% recovered in the urine as inactive water soluble metabolites, and the rest is eliminated in the feces as metabolites [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [5]
Metabolism
The drug is metabolized via the CYP3A4 [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.7123 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.044% [9]
Vd
The volume of distribution (Vd) of drug is 0.62-0.77 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.006 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Adverse drug reaction Not Available AHCYL1 OTX8L3M5 [10]
Gingival hyperplasia Not Available AR DHTR NR3C4 OTUBKAZZ [10]
Chemical Identifiers
Formula
C17H18N2O6
IUPAC Name
dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
InChI
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
InChIKey
HYIMSNHJOBLJNT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4485
ChEBI ID
CHEBI:7565
CAS Number
21829-25-4
UNII
I9ZF7L6G2L
DrugBank ID
DB01115
TTD ID
D04OSE
VARIDT ID
DR00396
INTEDE ID
DR1152
ACDINA ID
D00467
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated L-type calcium channel (L-CaC) TTXHYV6 NOUNIPROTAC Modulator [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [16]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Substrate [17], [18]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Drug Response [10]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Gene/Protein Processing [19]
Apolipoprotein A-II (APOA2) OTQ3HGTC APOA2_HUMAN Gene/Protein Processing [19]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [20]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Gene/Protein Processing [21]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [22]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [23]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [24]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [25]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [26]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CTRP1 4.9125 6.3648 4.2802 7.6485
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 5.5294 7.6165 4.1479 6.4517
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GaMG CTRP1 5.2519 6.8537 4.3168 5.9301
LN-229 CTRP1 6.3561 13.4493 1.8896 20.225
SF295 CTRP1 6.5431 7.8779 4.612 0.7228
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-6 CTRP1 3.425 4.0644 3.4229 23.3551
HEC-265 CTRP1 3.8947 4.7464 3.858 16.8985
HEC-151 CTRP1 4.1818 5.0409 4.1065 13.0938
KLE CTRP1 4.419 6.0795 3.9509 12.9909
MFE-319 CTRP1 4.4205 8.5594 2.7518 22.6923
JHUEM-2 CTRP1 4.5346 6.1934 4.0118 11.8561
HEC-251 CTRP1 4.7038 5.3864 4.5505 6.3005
HEC-108 CTRP1 4.7674 5.4834 4.5726 5.7599
HEC-59 CTRP1 5.302 6.4942 4.5324 3.8291
Ishikawa (Heraklio) 02 ER- CTRP1 4.196 6.2108 3.667 16.6257
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NU-DUL-1 CTRP1 1.3207 2.9037 1.3127 53.3499
OCI-AML-3 CTRP1 2.8451 3.9602 2.8323 31.7173
KE-97 CTRP1 3.0162 4.3724 2.9727 29.492
PL21 CTRP1 3.2832 4.8176 3.1812 26.116
SU-DHL-5 CTRP1 3.3072 4.7499 3.2219 25.6497
BL-70 CTRP1 3.3951 4.316 3.3796 23.8781
GDM-1 CTRP1 3.4234 4.92 3.3099 24.2051
Ku812 CTRP1 3.4288 4.5516 3.3883 23.5799
P3HR-1 CTRP1 3.5792 4.3072 3.5716 21.1915
THP-1 CTRP1 3.7355 4.6384 3.7039 19.1351
WSU-DLCL2 CTRP1 3.8916 4.8574 3.8338 17.1017
KMS-11 CTRP1 3.98 5.5075 3.7344 17.319
MC116 CTRP1 4.0848 4.8564 4.0435 14.2177
LP-1 CTRP1 4.1575 15.1172 -0.7399 37.7306
HT CTRP1 4.2725 5.0798 4.1949 11.8171
NOMO-1 CTRP1 4.4129 5.0325 4.3609 9.6171
SU-DHL-4 CTRP1 4.4656 5.1298 4.3907 9.0438
U-937 CTRP1 4.4968 6.4405 3.8577 13.3929
MOLM-16 CTRP1 4.5355 5.8215 4.1858 10.3426
RPMI-8226 CTRP1 4.5378 6.1905 4.0163 11.7999
SKM-1 CTRP1 4.5416 5.0342 4.5009 7.6939
EJM CTRP1 4.6214 5.3306 4.4871 7.3077
OCI-Ly10 CTRP1 6.6078 9.1605 4.1098 3.8725
AMO1 CTRP1 6.7751 7.7672 4.7409 0.1425
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RCC10RGB CTRP1 5.3805 7.2877 4.1999 6.5061
VMRC-RCW CTRP1 5.9293 8.8912 3.8107 8.0611
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW48 CTRP1 2.6317 4.821 2.471 35.7216
GP2d CTRP1 3.1306 4.7753 3.0246 28.3171
LS513 CTRP1 3.4494 4.7801 3.3699 23.5766
COLO 320 CTRP1 3.6084 6.141 2.6222 17.2788
DLD-1 CTRP1 3.7593 4.7242 3.716 18.8815
SNU-C5 CTRP1 4.4028 5.6101 4.1424 11.4507
LS411N CTRP1 4.4144 5.9288 4.0151 12.4647
HCT 116 CTRP1 4.4291 5.4935 4.2183 10.6653
CW-2 CTRP1 4.4687 5.3771 4.3067 9.7005
COLO 678 CTRP1 4.5147 5.5773 4.2728 9.7161
SNU-81 CTRP1 4.5192 5.5249 4.2998 9.4629
C2BBe1 CTRP1 4.5517 6.2353 4.0086 11.7954
COLO205 CTRP1 4.5553 5.4363 4.3745 8.6294
HT-55 CTRP1 4.5636 5.2007 4.4739 7.7656
LS123 CTRP1 4.5639 5.7879 4.2295 9.8125
LS180 CTRP1 4.5764 5.1179 4.5151 7.3581
SK-CO-1 CTRP1 4.6482 5.9788 4.2239 9.4166
SNU-175 CTRP1 4.6658 5.7612 4.3434 8.2844
RKO CTRP1 4.6802 5.3059 4.5593 6.364
LoVo CTRP1 4.6882 5.6074 4.4366 7.3591
SNU-C4 CTRP1 4.7599 5.8543 4.391 7.3839
HCT 8 CTRP1 4.8824 5.4885 4.6837 4.1908
SW948 CTRP1 4.8913 5.7387 4.5709 5.1451
CL-34 CTRP1 4.9475 5.8183 4.5828 4.7753
RCM-1 [Human ESC] CTRP1 5.005 6.5054 4.2902 7.1541
SNU-61 CTRP1 5.0538 6.0747 4.5467 4.6371
KM12 CTRP1 5.117 6.4832 4.3946 5.7509
SNU-1040 CTRP1 5.1494 7.6492 3.8384 10.5994
HT115 CTRP1 5.2381 6.3162 4.5727 3.6941
SW620 CTRP1 5.2997 6.7934 4.3832 5.1625
NCI-H508 CTRP1 5.3765 6.6042 4.5323 3.582
MDST8 CTRP1 5.4656 6.9701 4.4173 4.3005
SNU-C2A CTRP1 5.656 8.085 4.01 7.2336
SW480 CTRP1 5.7957 7.814 4.2364 4.8583
SW403 CTRP1 5.7986 8.7581 3.7836 8.7085
CL-40 CTRP1 5.8092 7.4841 4.3999 3.4569
HT-29 CTRP1 6.6015 7.7649 4.6777 0.3998
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-398 CTRP1 4.4997 10.0309 2.0928 26.4607
Hep-G2 CTRP1 5.0538 6.0962 4.536 4.7336
SNU-449 CTRP1 5.1458 7.2057 4.057 8.6691
JHH-6 CTRP1 5.3884 8.7518 3.4793 12.7486
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SHP-77 CTRP1 2.1858 5.8972 1.6602 43.077
NCI-H1963 CTRP1 2.5654 5.1281 2.3184 37.1327
NCI-H1105 CTRP1 2.9104 5.9988 2.404 34.0072
NCI-H1930 CTRP1 3.0965 5.1802 2.883 29.5758
COR-L51 CTRP1 3.2513 5.9532 2.786 29.2028
NCI-H1568 CTRP1 3.3645 5.855 2.9445 27.3311
Lu-99 CTRP1 3.7262 5.1083 3.5907 20.0552
NCI-H2029 CTRP1 3.7431 4.8464 3.6749 19.2989
NCI-H1048 CTRP1 3.7446 5.3433 3.5379 20.3505
NCI-H2141 CTRP1 3.7956 4.9086 3.7182 18.6205
NCI-H810 CTRP1 3.8433 5.3644 3.6379 18.9372
COLO 668 CTRP1 4.0534 5.9429 3.6379 17.6747
NCI-H358 CTRP1 4.1369 5.6753 3.8365 15.5428
NCI-H522 CTRP1 4.1406 6.9817 3.2553 20.3357
NCI-H82 CTRP1 4.1513 6.2766 3.5922 17.5021
NCI-H1355 CTRP1 4.17 7.527 3.0235 21.9917
HCC33 CTRP1 4.1825 5.7406 3.8576 15.1013
NCI-H23 CTRP1 4.1847 5.4553 3.9734 14.1339
VMRC-LCD CTRP1 4.2964 5.3116 4.1462 12.0513
NCI-H2286 CTRP1 4.3337 5.6524 4.0526 12.5993
Calu-6 CTRP1 4.3348 6.0488 3.8805 14.0508
SCLC-21H CTRP1 4.3476 5.3592 4.184 11.4331
NCI-H1876 CTRP1 4.352 5.7734 4.02 12.7708
NCI-H2122 CTRP1 4.4272 5.6297 4.1596 11.1669
NCI-H1435 CTRP1 4.43 7.2367 3.41 17.5622
NCI-H1694 CTRP1 4.4481 5.215 4.3439 9.5251
HCC78 CTRP1 4.4723 5.8947 4.0889 11.5168
NCI-H1944 CTRP1 4.4911 6.5851 3.783 14.0708
NCI-H1299 CTRP1 4.492 6.1181 4.0055 12.132
DMS 273 CTRP1 4.4988 5.403 4.3285 9.3416
NCI-H1373 CTRP1 4.5039 6.5259 3.8236 13.6526
NCI-H727 CTRP1 4.5317 6.5205 3.8528 13.2588
NCI-H596 CTRP1 4.5423 5.3553 4.3935 8.5484
HCC1195 CTRP1 4.5469 5.8401 4.1887 10.2556
LXF 289 CTRP1 4.5613 7.1214 3.5884 15.4047
NCI-H1836 CTRP1 4.5683 5.0751 4.5189 7.3799
ChaGo-K-1 CTRP1 4.6061 5.7629 4.2833 9.1217
COR-L23 CTRP1 4.6643 5.1947 4.5849 6.2506
NCI-H2081 CTRP1 4.6664 5.7811 4.3348 8.3556
LCLC-97TM1 CTRP1 4.677 7.718 3.399 16.4543
NCI-H2009 CTRP1 4.7199 6.611 3.9849 11.1747
HCC44 CTRP1 4.734 6.6606 3.9734 11.2104
EPLC-272H CTRP1 4.7924 6.3774 4.1662 9.2202
NCI-H2342 CTRP1 4.797 6.2394 4.2383 8.556
COR-L279 CTRP1 4.8014 6.1657 4.2785 8.1769
NCI-H1975 CTRP1 4.8291 6.4292 4.1739 8.9796
COLO 699 CTRP1 4.8659 5.7914 4.5215 5.7059
HARA [Human squamous cell lung carcinoma] CTRP1 4.8757 7.0592 3.9022 11.1934
LCLC-103H CTRP1 4.9056 5.7867 4.5605 5.1696
KNS-62 CTRP1 4.9209 6.7953 4.0731 9.4685
COR-L88 CTRP1 4.9212 7.1589 3.892 11.0838
NCI-H1755 CTRP1 4.9912 8.1414 3.4608 14.5246
HCC1359 CTRP1 4.9915 5.7267 4.6673 3.8187
NCI-H1437 CTRP1 4.9931 6.6323 4.2167 7.8657
HCC1833 CTRP1 5.0147 6.1662 4.468 5.5119
HCC4006 CTRP1 5.021 5.94 4.5863 4.4186
NCI-H441 CTRP1 5.0527 6.4051 4.3807 6.1384
HCC2108 CTRP1 5.0648 6.5136 4.3364 6.4872
NCI-H2405 CTRP1 5.0776 8.4399 3.3839 14.7975
NCI-H1666 CTRP1 5.1661 10.8372 2.2586 22.5216
LC-1/sq-SF CTRP1 5.1674 7.077 4.1388 7.8509
NCI-H1573 CTRP1 5.1782 10.3216 2.5263 20.7761
NCI-H2110 CTRP1 5.1962 12.1346 1.6348 25.8219
NCI-H1781 CTRP1 5.1994 6.9133 4.246 6.7644
EBC-1 CTRP1 5.2047 6.7544 4.3294 5.9954
CAL-12T CTRP1 5.2384 6.6735 4.3959 5.273
NCI-H661 CTRP1 5.2387 7.4448 4.0123 8.7027
SK-LU-1 CTRP1 5.2793 8.4537 3.5414 12.653
NCI-H650 CTRP1 5.2851 6.8695 4.3344 5.6505
BEN CTRP1 5.2997 7.5635 4.0011 8.5689
A-549 CTRP1 5.3718 6.8035 4.4316 4.4823
NCI-H1792 CTRP1 5.4029 9.1037 3.3155 14.04
NCI-H3255 CTRP1 5.5907 7.2044 4.3904 4.1466
NCI-H2126 CTRP1 5.592 7.5981 4.2015 5.7768
HCC15 CTRP1 5.6186 7.701 4.1702 5.9638
Lu-65 CTRP1 5.6211 8.8173 3.6252 10.6589
NCI-H1793 CTRP1 5.6882 8.048 4.0508 6.7759
Sq-1 CTRP1 5.7038 7.7212 4.2193 5.2749
NCI-H1915 CTRP1 5.7048 10.2202 2.9948 15.3932
NCI-H2030 CTRP1 5.7129 7.5519 4.3063 4.5049
NCI-H2073 CTRP1 5.7724 7.9406 4.1606 5.5704
Calu-3 CTRP1 5.9157 8.3138 4.0781 5.8469
HCC827 CTRP1 5.9483 8.2185 4.1445 5.1982
NCI-H841 CTRP1 6.0783 8.0469 4.3047 3.5569
T3M-10 CTRP1 6.2279 9.7414 3.6056 8.84
HCC2935 CTRP1 6.2298 8.0036 4.4098 2.4285
RERF-LC-KJ CTRP1 6.3022 9.871 3.5935 8.7165
NCI-H2172 CTRP1 6.5468 9.1121 4.0969 4.1003
NCI-H2023 CTRP1 6.71 8.5257 4.4319 1.5008
NCI-H460 CTRP1 6.7577 7.8482 4.7068 0.2276
DV-90 CTRP1 7.4517 9.8591 4.2394 1.667
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-140 CTRP1 4.016 5.6868 3.7039 17.3497
KYSE-450 CTRP1 4.8679 5.6965 4.5697 5.2688
KYSE-410 CTRP1 5.8968 7.9044 4.2591 4.3859
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVK18 CTRP1 2.7688 4.2144 2.7295 32.9926
OVCAR-8 CTRP1 3.9733 5.8349 3.599 18.4637
OVCAR-4 CTRP1 4.0329 5.0778 3.934 15.4001
COV434 CTRP1 4.097 5.7536 3.7625 16.3903
HEY A8 CTRP1 4.1438 5.0255 4.0691 13.6297
JHOS-4 CTRP1 4.1978 6.1415 3.6999 16.3378
JHOM-1 CTRP1 4.231 6.7425 3.4564 18.2064
JHOC-5 CTRP1 4.3936 5.6348 4.1225 11.6709
EFO-27 CTRP1 4.3961 6.5987 3.6851 15.4041
RMUG-S CTRP1 4.5705 5.4669 4.3777 8.5159
OVKATE CTRP1 4.6109 5.5141 4.3995 8.1017
TYK-nu CTRP1 4.6463 5.4103 4.4806 7.2169
RMG-I CTRP1 4.6902 5.7378 4.3784 7.8523
COV644 CTRP1 4.7009 5.2994 4.5837 6.0403
OV-90 CTRP1 4.7141 5.388 4.5605 6.1589
SNU-840 CTRP1 4.7874 6.0501 4.3221 7.8566
A2780 CTRP1 4.8875 6.1704 4.3546 7.0948
COV318 CTRP1 5.3317 6.9995 4.3055 5.74
IGROV-1 CTRP1 5.442 7.1928 4.2919 5.4783
SK-OV-3 CTRP1 5.4488 7.6476 4.0733 7.3849
Caov-3 CTRP1 5.6728 8.2398 3.9465 7.7284
OV7 CTRP1 5.7991 7.8091 4.2409 4.8103
COV362 CTRP1 5.9336 8.4192 4.0399 6.1174
OVMANA CTRP1 6.3225 8.8556 4.0816 4.7353
OAW42 CTRP1 6.6054 7.8582 4.6451 0.5235
EFO-21 CTRP1 6.8219 9.2434 4.189 2.8903
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Capan-2 CTRP1 4.3212 6.4227 3.6949 15.7103
Panc 03.27 CTRP1 4.3982 5.2302 4.2848 10.308
HuP-T4 CTRP1 4.4705 6.0799 4.002 12.2756
PaTu 8902 CTRP1 4.5074 5.5979 4.2563 9.8958
Panc 10.05 CTRP1 4.6038 5.4021 4.4396 7.8052
KP-3 CTRP1 4.6754 8.2068 3.1549 18.4447
QGP-1 CTRP1 5.1784 7.9318 3.7207 11.5139
CFPAC-1 CTRP1 5.495 8.0524 3.9082 8.672
HPAC CTRP1 5.5602 7.8455 4.0581 7.1341
SUIT-2 CTRP1 5.893 7.2653 4.5488 2.0835
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP1 3.7989 5.2201 3.6366 19.2291
NCI-H28 CTRP1 5.1519 7.6113 3.8593 10.4044
NCI-H2052 CTRP1 5.4826 7.505 4.1684 6.4288
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP1 4.8027 6.1458 4.2895 8.0722
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 741 CTRP1 3.9474 6.6575 3.214 21.7349
Hs 852.T CTRP1 4.0439 5.7917 3.691 17.2902
A-375 CTRP1 4.5594 5.2244 4.461 7.8949
SK-MEL-1 CTRP1 4.5661 5.3834 4.4075 8.2927
G-361 CTRP1 4.8251 6.8822 3.9457 11.0343
SK-MEL-5 CTRP1 5.2487 6.414 4.5323 4.0167
Hs 944.T CTRP1 5.4784 6.9491 4.4365 4.0924
Hs 936.T CTRP1 5.7002 10.8728 2.6676 17.7559
SK-MEL-28 CTRP1 5.9491 7.9999 4.2475 4.3425
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-401 CTRP1 3.1024 6.1261 2.5605 31.6999
RKN CTRP1 4.4118 5.0271 4.3612 9.6217
HT-1080 CTRP1 4.9286 6.5935 4.1805 8.4719
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AGS CTRP1 4.2307 4.8572 4.2011 12.0485
MKN7 CTRP1 5.1219 6.7543 4.2631 6.915
MKN74 CTRP1 5.8204 8.5543 3.8979 7.666
Fu97 CTRP1 5.8924 9.4634 3.5067 10.7074
SH-10-TC CTRP1 6.0857 7.8488 4.3982 2.8125
NUGC-4 CTRP1 6.3437 8.2647 4.3577 2.5845
SNG-M CTRP1 5.8041 7.5967 4.3443 3.9298
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP1 4.2663 4.8636 4.2384 11.526
SCC-9 CTRP1 5.2822 6.649 4.4414 4.7073
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1376 CTRP1 4.0813 6.0926 3.6023 17.8103
RT-4 CTRP1 4.159 5.6907 3.8535 15.2725
5637 CTRP1 4.6621 6.5334 3.9695 11.5889
UM-UC-3 CTRP1 4.9794 5.8753 4.5827 4.6322
KMBC-2 CTRP1 5.6141 9.4189 3.3225 13.1837

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nifedipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Pioglitazone DMKJ485 Minor Altered absorption of Nifedipine caused by Pioglitazone. Acute diabete complication [5A2Y] [27]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Nifedipine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [28]
Midostaurin DMI6E0R Moderate Decreased metabolism of Nifedipine caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [29]
Idarubicin DMM0XGL Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [30]
Arn-509 DMT81LZ Major Increased metabolism of Nifedipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [31]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [32]
Emapalumab DMZG5WL Moderate Altered metabolism of Nifedipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [32]
Siltuximab DMGEATB Moderate Altered metabolism of Nifedipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [32]
Cilostazol DMZMSCT Moderate Decreased metabolism of Nifedipine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [33]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nifedipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [34]
Budesonide DMJIBAW Moderate Decreased metabolism of Nifedipine caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [35]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nifedipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Nifedipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [37]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Nifedipine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [37]
Cariprazine DMJYDVK Moderate Decreased metabolism of Nifedipine caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [38]
Erdafitinib DMI782S Moderate Increased metabolism of Nifedipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [39]
Pexidartinib DMS2J0Z Major Decreased metabolism of Nifedipine caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [40]
Talazoparib DM1KS78 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [41]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Nifedipine caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Nifedipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Tucatinib DMBESUA Moderate Decreased metabolism of Nifedipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Palbociclib DMD7L94 Moderate Decreased metabolism of Nifedipine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Nifedipine caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Bosutinib DMTI8YE Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [32]
Macitentan DMP79A1 Moderate Decreased metabolism of Nifedipine caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [46]
PF-04449913 DMSB068 Moderate Decreased metabolism of Nifedipine caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [47]
Indacaterol DMQJHR7 Minor Decreased clearance of Nifedipine due to the transporter inhibition by Indacaterol. Chronic obstructive pulmonary disease [CA22] [48]
Fidaxomicin DMFP6MV Minor Decreased clearance of Nifedipine due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [49]
Intedanib DMSTA36 Moderate Decreased metabolism of Nifedipine caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [50]
Ulipristal DMBNI20 Minor Decreased metabolism of Nifedipine caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [32]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Nifedipine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [32]
Lumacaftor DMCLWDJ Major Increased metabolism of Nifedipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [31]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nifedipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [51]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nifedipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [52]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [53]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Nifedipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [54]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Nifedipine and Isocarboxazid. Depression [6A70-6A7Z] [55]
Escitalopram DMFK9HG Minor Decreased metabolism of Nifedipine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [56]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Nifedipine and OPC-34712. Depression [6A70-6A7Z] [57]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Nifedipine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [58]
Cenobamate DM8KLU9 Moderate Increased metabolism of Nifedipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nifedipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Fosphenytoin DMOX3LB Major Increased metabolism of Nifedipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Rufinamide DMWE60C Moderate Increased metabolism of Nifedipine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Phenobarbital DMXZOCG Major Increased metabolism of Nifedipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Nifedipine and Nadolol. Essential hypertension [BA00] [60]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nifedipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [61]
Solifenacin DMG592Q Moderate Decreased metabolism of Nifedipine caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [62]
Mirabegron DMS1GYT Minor Decreased metabolism of Nifedipine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [63]
Ripretinib DM958QB Moderate Decreased metabolism of Nifedipine caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [49]
Avapritinib DMK2GZX Moderate Decreased metabolism of Nifedipine caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [32]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Nifedipine and Metipranolol. Glaucoma [9C61] [64]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Nifedipine and Levobetaxolol. Glaucoma [9C61] [64]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Nifedipine and Levobunolol. Glaucoma [9C61] [64]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Nifedipine and Carvedilol. Heart failure [BD10-BD1Z] [60]
Boceprevir DMBSHMF Moderate Decreased metabolism of Nifedipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [65]
Simeprevir DMLUA9D Moderate Decreased metabolism of Nifedipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [66]
Telaprevir DMMRV29 Moderate Decreased metabolism of Nifedipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [65]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Nifedipine caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [49]
Rifapentine DMCHV4I Major Increased metabolism of Nifedipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [31]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Nifedipine and Procarbazine. Hodgkin lymphoma [2B30] [55]
MK-1439 DM215WE Minor Decreased metabolism of Nifedipine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Nifedipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Cobicistat DM6L4H2 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [69]
Dolutegravir DMCZGRE Minor Decreased metabolism of Nifedipine caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Saquinavir DMG814N Moderate Decreased metabolism of Nifedipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
Etravirine DMGV8QU Moderate Increased metabolism of Nifedipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Nifedipine caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Darunavir DMN3GCH Moderate Decreased metabolism of Nifedipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Maraviroc DMTL94F Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [74]
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Nifedipine and Acebutolol. Hypertension [BA00-BA04] [60]
Aliskiren DM1BV7W Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [75]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Nifedipine and Penbutolol. Hypertension [BA00-BA04] [60]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Nifedipine and Nebivolol. Hypertension [BA00-BA04] [60]
Tolvaptan DMIWFRL Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [76]
Retapamulin DM9JXB7 Minor Decreased metabolism of Nifedipine caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [77]
Lesinurad DMUR64T Moderate Increased metabolism of Nifedipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [78]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Nifedipine caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [49]
Amobarbital DM0GQ8N Moderate Increased metabolism of Nifedipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [79]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Nifedipine caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [80]
Naloxegol DML0B41 Minor Decreased clearance of Nifedipine due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [81]
Pemigatinib DM819JF Moderate Decreased metabolism of Nifedipine caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [32]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nifedipine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [82]
Osimertinib DMRJLAT Moderate Decreased metabolism of Nifedipine caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [83]
Selpercatinib DMZR15V Moderate Decreased metabolism of Nifedipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
Idelalisib DM602WT Moderate Decreased metabolism of Nifedipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
GDC-0199 DMH0QKA Major Decreased metabolism of Nifedipine caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [49]
IPI-145 DMWA24P Moderate Decreased metabolism of Nifedipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [85]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Nifedipine caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [86]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Nifedipine caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [87]
Arry-162 DM1P6FR Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Arry-162. Melanoma [2C30] [49]
Selumetinib DMC7W6R Moderate Decreased metabolism of Nifedipine caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [88]
LGX818 DMNQXV8 Moderate Increased metabolism of Nifedipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [89]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nifedipine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [32]
Ubrogepant DM749I3 Moderate Decreased metabolism of Nifedipine caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [90]
Exjade DMHPRWG Moderate Decreased metabolism of Nifedipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [91]
Flibanserin DM70DTN Moderate Decreased metabolism of Nifedipine caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [92]
Panobinostat DM58WKG Moderate Decreased metabolism of Nifedipine caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [93]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Nifedipine and Siponimod. Multiple sclerosis [8A40] [49]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Nifedipine and Fingolimod. Multiple sclerosis [8A40] [94]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Nifedipine and Ozanimod. Multiple sclerosis [8A40] [95]
Romidepsin DMT5GNL Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [96]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nifedipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Nilotinib DM7HXWT Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [97]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Nifedipine caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Dasatinib DMJV2EK Moderate Decreased metabolism of Nifedipine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [98]
Entrectinib DMMPTLH Moderate Decreased metabolism of Nifedipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [99]
S-297995 DM26IH8 Moderate Decreased clearance of Nifedipine due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [32]
Olaparib DM8QB1D Moderate Decreased metabolism of Nifedipine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [100]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nifedipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [101]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Nifedipine and Safinamide. Parkinsonism [8A00] [55]
Istradefylline DM20VSK Moderate Decreased metabolism of Nifedipine caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [102]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Nifedipine and Rasagiline. Parkinsonism [8A00] [55]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Nifedipine caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [103]
Abametapir DM2RX0I Moderate Decreased metabolism of Nifedipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [104]
Lefamulin DME6G97 Moderate Decreased metabolism of Nifedipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [105]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Nifedipine caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [106]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Nifedipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [107]
Enzalutamide DMGL19D Major Increased metabolism of Nifedipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [31]
Darolutamide DMV7YFT Minor Decreased clearance of Nifedipine due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [108]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Nifedipine caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [109]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Nifedipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [32]
Ixekizumab DMXW92T Moderate Altered metabolism of Nifedipine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [32]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Nifedipine and Levomepromazine. Psychotic disorder [6A20-6A25] [57]
Axitinib DMGVH6N Moderate Decreased metabolism of Nifedipine caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [32]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Nifedipine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [110]
Upadacitinib DM32B5U Moderate Decreased metabolism of Nifedipine caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [111]
Tocilizumab DM7J6OR Moderate Altered metabolism of Nifedipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Canakinumab DM8HLO5 Moderate Altered metabolism of Nifedipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Rilonacept DMGLUQS Moderate Altered metabolism of Nifedipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Golimumab DMHZV7X Moderate Altered metabolism of Nifedipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Sarilumab DMOGNXY Moderate Altered metabolism of Nifedipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Quetiapine DM1N62C Moderate Decreased metabolism of Nifedipine caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [112]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Nifedipine and Aripiprazole. Schizophrenia [6A20] [57]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Nifedipine and Iloperidone. Schizophrenia [6A20] [57]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Nifedipine and Paliperidone. Schizophrenia [6A20] [57]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Nifedipine and Molindone. Schizophrenia [6A20] [57]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Nifedipine and Thiothixene. Schizophrenia [6A20] [57]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Nifedipine and Amisulpride. Schizophrenia [6A20] [57]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Nifedipine and Asenapine. Schizophrenia [6A20] [57]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Nifedipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [113]
LDE225 DMM9F25 Moderate Decreased metabolism of Nifedipine caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [114]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nifedipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [32]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nifedipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Docetaxel DMDI269 Moderate Decreased metabolism of Nifedipine caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [115]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Nifedipine caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Armodafinil DMGB035 Moderate Increased metabolism of Nifedipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
LEE011 DMMX75K Moderate Decreased metabolism of Nifedipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Taxol DMUOT9V Moderate Decreased metabolism of Nifedipine caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [116]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nifedipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [32]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Nifedipine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [117]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [101]
Apixaban DM89JLN Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [32]
Saxagliptin DMGXENV Moderate Decreased metabolism of Nifedipine caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [32]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Nifedipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [118]
Betrixaban DM2C4RF Moderate Decreased clearance of Nifedipine due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [119]
⏷ Show the Full List of 156 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
Ethyl acrylate E00191 8821 Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Menthol E00050 1254 Flavoring agent
methylparaben E00149 7456 Antimicrobial preservative
Potassium chloride E00074 4873 Tonicity agent
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric trioxide E00437 518696 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Isobutyl alcohol E00130 6560 Flavoring agent; Solvent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Methyl methacrylate E00133 6658 Film/membrane-forming agent
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 43 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nifedipine 10 mg capsule 10 mg Oral Capsule Oral
Nifedipine 60 mg tablet 60 mg 24 HR Extended Release Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg 24 HR Extended Release Oral Tablet Oral
Nifedipine 20 mg capsule 20 mg Oral Capsule Oral
Nifedipine 90 mg tablet 90 mg 24 HR Extended Release Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg Osmotic 24 HR Extended Release Oral Tablet Oral
Nifedipine 60 mg tablet 60 mg Osmotic 24 HR Extended Release Oral Tablet Oral
Nifedipine 90 mg tablet 90 mg Osmotic 24 HR Extended Release Oral Tablet Oral
Nifedipine 30 mg tablet 30 mg 24 HR Extended Release Tablet Oral
Nifedipine 60 mg tablet 60 mg 24 HR Extended Release Tablet Oral
Nifedipine 90 mg tablet 90 mg 24 HR Extended Release Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2514).
2 Nifedipine FDA Label
3 van Harten J, Burggraaf K, Danhof M, van Brummelen P, Breimer DD: Negligible sublingual absorption of nifedipine. Lancet. 1987 Dec 12;2(8572):1363-5. doi: 10.1016/s0140-6736(87)91258-x.
4 BDDCS applied to over 900 drugs
5 Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am J Med. 1987 Dec 21;83(6B):10-4. doi: 10.1016/0002-9343(87)90630-9.
6 FDA Approved Drug Products: Procardia XL Nifedipine Oral Extended Release Tablets
7 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008 Feb;36(2):386-99. doi: 10.1124/dmd.107.019083. Epub 2007 Nov 15.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13 Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
14 Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
15 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
16 In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
17 Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
18 The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
19 Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. Angiology. 1991 Sep;42(9):681-90. doi: 10.1177/000331979104200901.
20 Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Am J Hypertens. 1999 Jan;12(1 Pt 1):73-5. doi: 10.1016/s0895-7061(98)00217-9.
21 Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. doi: 10.1124/dmd.31.11.1296.
22 Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.
23 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
24 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
25 High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
26 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
27 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
28 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
29 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
30 Multum Information Services, Inc. Expert Review Panel.
31 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
34 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
35 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
36 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
37 Geronimo-Pardo M, Cuartero-Del-Pozo AB, Jimenez-Vizuete JM, Cortinas-Saez M, Peyro-Garcia R "Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock." Ann Pharmacother 39 (2005): 538-42. [PMID: 15703161]
38 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
39 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
40 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
41 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
43 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
45 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
46 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
49 Cerner Multum, Inc. "Australian Product Information.".
50 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
51 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
52 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
53 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
54 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
55 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
56 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
57 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
58 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
59 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
60 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
61 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
62 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
63 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
64 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
65 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
66 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
67 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
68 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
69 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
70 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
71 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
72 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
73 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
74 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Canadian Pharmacists Association.
76 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
77 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
78 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
79 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
80 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
81 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
82 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
83 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
84 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
85 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
86 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
87 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
88 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
89 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
90 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
91 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
92 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
93 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
94 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
95 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
96 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
97 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
98 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
99 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
100 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
101 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
102 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
103 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
104 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
105 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
106 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
107 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
108 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
109 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
110 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
111 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
112 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
113 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
114 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
115 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
116 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
117 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
118 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
119 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.